Speciality Medicines IPO Closing Today: A Deep Value Pharma Play or a Quiet SME Debut?
Mumbai-based Speciality Medicines Limited wraps up its ₹29.14 crore SME IPO today, March 24, 2026. With a portfolio of 900+ products and a massive 3x jump in profit last year, the company is looking to build its own R&D center. We dive into the current 1x subscription status, the flat GMP, and the long-term outlook for this specialty pharma distributor.
Live IPO Tracking Available
Check live GMP, allotment status, and deep analysis for this IPO.
1. Final Countdown: Today is Day 3
If you are planning to bid, today is the last chance before the window closes at 5:00 PM.
Subscription Status (Mid-Day): As of today, the issue is overall subscribed approximately 1.03x.
The Mixed Bag: Big HNI (bHNI) investors have shown the most enthusiasm (over 2.6x), while retail participation has been surprisingly slow at just around 0.2x. This suggests that professional investors see value in the fundamentals, while retail traders might be staying away due to the lack of "listing gain" buzz.
2. What Does the Company Actually Do?
Speciality Medicines isn't a traditional manufacturer yet. They are a powerhouse in the marketing and distribution of high-cost, critical-care medications.
Niche Focus: They specialize in therapies that are often hard to find or require strict temperature controls, such as Oncology (Cancer), Immunology, and Neurology.
The "Asset-Light" Model: They currently use third-party manufacturers to produce their own brands, which keeps their costs low and allows them to export to over 35 countries.
The Future: A huge chunk of the IPO money (₹12.67 crore) is earmarked to build their own R&D Center in Gujarat, moving them from being "traders" to "developers."
3. Grey Market Check: Keeping it Real
Current GMP: ₹0 (as of March 24 morning).
Estimated Listing: ₹124 (0% gain).
What this means: The "Grey Market" isn't predicting a fireworks show on listing day. It indicates that the IPO is priced very close to its fair value. This is a stock for those who believe in the company’s 3-year growth story, rather than those looking to double their money on Monday.
4. IPO Timeline & Application Essentials
| Event / Detail | Dates & Information |
|---|---|
| IPO Closing Date | Today, Tuesday, March 24, 2026 |
| Price Band | ₹117 to ₹124 per share |
| Minimum Lot Size | 1,000 Shares |
| Retail Min. Investment | ₹2,48,000 (2 Lots / 2,000 Shares) |
| Allotment Date | Wednesday, March 25, 2026 |
| Listing Date | Monday, March 30, 2026 (BSE SME) |
5. Financials: The "Eye-Popping" Growth
The company's numbers have taken a massive leap recently, which has some analysts raising eyebrows:
Revenue: Jumped from ₹27 crore in FY24 to ₹58 crore in FY25.
Profit (PAT): Grew nearly 3x from ₹2.93 crore to ₹8.61 crore.
Valuation: At the upper price of ₹124, the P/E ratio is around 9.27x. Compared to peers like Remus Pharmaceuticals (which trades at 10x+), Speciality Medicines actually looks quite attractively priced.
6. Risks to Watch Out For
No Manufacturing: Since they rely on others to make their medicines, any quality issue at a partner factory could hurt their reputation.
Concentration: A large portion of their revenue comes from a small group of key customers.
SME Liquidity: Being an SME stock, it may be harder to sell large quantities quickly after listing compared to a mainboard stock.